

# Expression Patterns and Prognostic Value of RUNX Genes in Kidney Cancer

**Ke Gao**

Department of Urology, the Second Affiliated Hospital of Xi'an Jiaotong University

**Fang Zhang**

Department of Tumor 2 families, the Central Hospital of Enshi Tujia and Miao Autonomous Prefecture

**Ke Chen**

Department of Medical Ultrasonic, the Second Affiliated Hospital of Xi'an Jiaotong University

**Wei Li**

Department of Anesthesia, the Second Affiliated Hospital of Xi'an Jiaotong University

**Yi-Bing Guan**

Department of Urology, the Second Affiliated Hospital of Xi'an Jiaotong University

**Meng-Lu Xu**

Department of Nephrology, the First Affiliated Hospital of Xi'an Medical University

**Tie Chong**

Department of Urology, the Second Affiliated Hospital of Xi'an Jiaotong University

**Zhi-Ming Dai** (✉ [daizhiming2016@xjtu.edu.cn](mailto:daizhiming2016@xjtu.edu.cn))

Department of Anesthesia, the Second Affiliated Hospital of Xi'an Jiaotong University

---

## Research Article

**Keywords:** RUNX genes, renal clear cell carcinoma, methylation, prognosis, integrative analysis

**Posted Date:** January 25th, 2021

**DOI:** <https://doi.org/10.21203/rs.3.rs-152365/v1>

**License:**  This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

---

**Version of Record:** A version of this preprint was published at Scientific Reports on July 22nd, 2021. See the published version at <https://doi.org/10.1038/s41598-021-94294-2>.

# Expression Patterns and Prognostic Value of *RUNX* Genes in Kidney Cancer

Ke Gao<sup>1,2†</sup>, Fang Zhang<sup>3,†</sup>, Ke Chen<sup>4,†</sup>, Wei Li<sup>1</sup>, Yi-Bing Guan<sup>2</sup>, Meng-Lu Xu<sup>5</sup>, Tie Chong<sup>2,\*</sup>, and  
Zhi-Ming Dai<sup>1,\*</sup>,

<sup>1</sup> Department of Anesthesia, the Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710004, China;

<sup>2</sup> Department of Urology, the Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710004, China;

<sup>3</sup> Department of Tumor 2 families, the Central Hospital of Enshi Tujia and Miao Autonomous Prefecture, Enshi 445000, China;

<sup>4</sup> Department of Medical Ultrasonic, the Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710004, China;

<sup>5</sup> Department of Nephrology, the First Affiliated Hospital of Xi'an Medical University, Xi'an 710003, China

† These authors have contributed equally to this work.

\* Address of correspondence: Zhi-Ming Dai, MD, Department of Anesthesia, the Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710004, China. Phone No.: 86-29-8767-9696. E-Mail ID: daizhiming2016@xjtu.edu.cn.

Co-corresponding author: Dr. Tie Chong, E-Mail ID: chongtie@126.com.

**Running title:** *RUNX* genes and kidney cancer

## **Abstract**

Kidney cancer is the third most common malignancy of the urinary system, of which, kidney renal clear cell carcinoma (KIRC) accounts for the vast majority. Runt-related transcription factors (RUNX) are involved in multiple cellular functions. However, the diverse expression patterns and prognostic values of *RUNX* genes in kidney cancer remained to be elucidated. In our study, we mined the DNA methylation, transcriptional and survival data of *RUNX* genes in patients with different kinds of kidney cancer through OncoPrint, Gene Expression Profiling Interactive Analysis, UALCAN, Kaplan-Meier Plotter, cBioPortal and LinkedOmics. We found that *RUNX1* and *RUNX3* were upregulated in KIRC tissues compared with those in normal tissues. The survival analysis results indicated a high transcription level of *RUNX1* was associated with poor overall survival (OS) in KIRC patients. Furthermore, KIRC tumor tissues had significantly lower levels of *RUNX1* promoter methylation than that in paracancerous tissues, with decreased DNA methylation of *RUNX1* notably associated with poor OS in KIRC. In conclusion, our results revealed that *RUNX1* may be a potential therapeutic target for treating KIRC, and *RUNX1* promoter methylation level shows promise as a novel diagnostic and prognostic biomarker, which laid a foundation for further study.

**Keywords** *RUNX* genes, renal clear cell carcinoma, methylation, prognosis, integrative analysis

## Introduction

Kidney cancer is the third commonest malignancy of the urinary system and has morbidity and mortality rates of 2.2% and 1.8%, respectively<sup>[1]</sup>. Kidney renal clear cell carcinoma (KIRC) is the most common kidney cancer, accounting for 80-90% of total renal cell carcinoma (RCC) cases<sup>[2]</sup>. Due to the lack of specific clinical symptoms in the early stage, about 30% of the patients with this disease have metastasis at the time of diagnosis, almost 40% of which are prone to postoperative recurrence<sup>[3]</sup>. Meanwhile, advanced metastatic or recurrent RCC has limited treatment, since it is not sensitive to radiation nor chemotherapy. Though targeted therapy has modest improvement over previous cytokine therapies, the outlook for high-risk patients remains poor. Therefore, it is urgent to identify biomarkers for early diagnosis and prognosis of RCC. Epigenetic alterations, such as abnormal DNA methylation, play an important role in the development and progression of kidney cancer, thus, they are considered as potential biomarkers for RCC early diagnosis and for monitoring prognosis.

Runt-related transcription factors (RUNX) are named after the discovery of the developmental regulatory gene *runt*. They have been reported to be vital in leukemia and solid tumors derived from different organs. To date, RUNX family members (*RUNX1*, *RUNX2*, *RUNX3*) have been revealed in diverse developmental process, including cell proliferation, differentiation and apoptosis<sup>[4]</sup>. Abnormal methylation status of *RUNX* genes has been found in several cancers including prostate cancer<sup>[5]</sup>, esophageal cancer<sup>[6]</sup> and breast cancer<sup>[7]</sup>, which may affect their expression levels. Some studies considered *RUNX1* as not only a tumor-suppressive factor but also an oncogenic factor<sup>[8-10]</sup>. For instance, in lung cancer, missing *RUNX1* was found to result in enhanced proliferation, migration, and invasion of tumor cells<sup>[11]</sup>, while it was regarded as a tumor suppressor connected with stabilization of Axis inhibition protein1 (*AXINI*) expression<sup>[12]</sup>. Meanwhile, high *RUNX1* expression level was found correlating with poor prognosis in triple-negative breast cancer<sup>[13]</sup>. Furthermore, the evidence has proved that RUNX proteins displayed various post-translational modifications such as acetylation<sup>[14]</sup>, methylation<sup>[15]</sup>, phosphorylation<sup>[16]</sup> and sumoylation<sup>[17]</sup>. All of these contribute to the functional complexity of *RUNX* genes.

So far, a few studies have investigated the expression profiles of *RUNX* genes in RCC<sup>[18, 19]</sup>. However, the relationship between *RUNX* genes and the onset, progression and prognosis of RCC remains controversial. Therefore, our study aimed to analyze the connection between the expression levels of *RUNX* genes and clinicopathological parameters of RCC especially KIRC patients by multi-

dimensional analysis methods, and conducted a preliminary analysis of their regulation and potential functions.

## **Materials and methods**

### **Pan-cancer analysis of expression levels of *RUNX* genes by OncoPrint and Gene Expression Profiling Interactive Analysis (GEPIA)**

OncoPrint (<https://www.oncoPrint.org/>) is a platform that provides solutions for individual researchers and multinational companies with robust peer-reviewed analysis methods as well as a powerful set of analysis functions that compute gene expression signatures, clusters and gene-set modules and that allow extracting biological insights from the data automatically. This database contains 715 datasets, 86,733 normal and tumor samples<sup>[20]</sup>. Pan-cancer analysis was performed to assess the transcriptional levels of *RUNX* genes in different types of cancer and corresponding normal tissues using OncoPrint. GEPIA (<http://gepia.cancer-pku.cn/>) is an interactive web server for analyzing the RNA sequencing expression data of 9,736 tumors and 8,587 normal samples from the TCGA and the GTEx projects by using a standard processing pipeline<sup>[21]</sup>. We utilized GEPIA in this study to verify the relationship between the expression of *RUNX* genes and kidney cancer.

### **Kaplan-Meier plotter (KM plotter), UALCAN, cBio Cancer Genomics Portal (cBioPortal) and CPTAC analyses**

The prognostic value of *RUNX* mRNA expression was analyzed using the KM Plotter database (<http://kmplot.com/analysis/>), which contains 54,000 gene expression data and survival information in 21 cancer types<sup>[22]</sup>. UALCAN (<http://ualcan.path.uab.edu/index.html>) is an interactive web resource for analyzing cancer data and providing gene expression analysis by using TCGA datasets (<https://www.cancer.gov/>)<sup>[23]</sup>. The cBioPortal (<http://www.cbioportal.org/>) is an open access for interactive exploration of multiple cancer genomics data sets, currently covering 282 cancer researches<sup>[24]</sup>. The UALCAN and cBioPortal database was used to explore the relationship between the promoter methylation status and its mRNA expression of *RUNX1* gene. The Beta value indicates level of DNA methylation ranging from 0 (unmethylated) to 1 (fully methylated). Different beta value cut-off has been considered to indicate hyper-methylation (Beta value: 0.7 - 0.5) or hypo-methylation (Beta-value: 0.3 - 0.25)<sup>[25, 26]</sup>. The National Cancer Institute's Clinical Proteomic Tumor Analysis Consortium (CPTAC, <https://proteomics.cancer.gov/>) is a public data portal of proteomic sequence and

corresponding genomic sequence datasets. Using CPTAC, we mined the protein expression of *RUNX* genes. Then we obtained and downloaded the clinical and FPKM-standardized RNA-seq data and the clinical information of 531 KIRC patients from the TCGA database. The clinical data were preprocessed by removal of samples without survival status and patients with survival time less than 30 days were also excluded because they might die of non-cancer-related diseases. Furthermore, we performed univariate and multivariate Cox regression analysis to demonstrate the correlations between OS and clinical variables.

### **LinkedOmics analysis and Gene Set Enrichment Analysis (GSEA)**

LinkedOmics (<http://linkedomics.org/login.php>) is a publicly available portal that includes multi-omics data from all 32 TCGA cancer types<sup>[27]</sup>. LinkedOmics was used to investigate the transcription networks of *RUNX1* in KIRC. Data from the LinkFinder results were signed and ranked, meanwhile GSEA was used to perform Gene Ontology (GO), Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways, transcription factor-target enrichment and kinase-target enrichment. The statistical analyses were based on the Molecular Signatures Database (MSigDB)<sup>[28]</sup>; 1000 simulations were performed and False discovery rate (FDR < 0.05) was used to select significantly enriched gene sets.

## **Results**

### **Analysis of expression level of *RUNX* genes in pan-cancer**

As shown in Figure 1, the results showed 460, 450 and 447 total unique analyses for *RUNX1*, *RUNX2*, *RUNX3* respectively. Pan-cancer analysis results showed that *RUNX1* increased significantly in 58 datasets, especially those of leukemia, head and neck cancer, colorectal cancer, kidney cancer, and breast cancer. As for *RUNX2*, 24 datasets displayed increased expression, whereas 14 datasets showed the opposite results. Similarly, higher expression of *RUNX3* was found in 19 datasets, while lower expression was found in 10 datasets. Overall, the obtained results indicated significantly elevated expression of *RUNX1* (with fold changes of 6.58 to 6.51) and *RUNX3* (with fold changes of 2.7 to 8.32) in kidney cancer (Table 1).

### **Verification of expression of *RUNX* genes in kidney cancer**

To further verify differential expression of *RUNX* genes in kidney cancer, we compared expression profiles of each gene between different kinds of kidney cancer samples and paired normal tissues by GEPIA. The results indicated that *RUNX1* and *RUNX3* were significantly overexpressed in

KIRC (Figure 2A, 2C). For *RUNX2*, no significant expression difference was found (Figure 2B). Furthermore, the relationship between expressions of *RUNX1* and *RUNX3* and prognosis of KIRC were performed by KM plotter and the results revealed that higher expression of *RUNX1* had poorer overall survive (OS) in KIRC patients ( $p = 0.0048$ , Figure 2D), whereas there was no significant relation between *RUNX3* and OS in these patients ( $p=0.15$ , Figure 2E).

### **Correlation analysis between *RUNX1* and clinicopathological characteristics in KIRC**

Table 2 showed the basic clinical characteristics. In total, we identified 531 KIRC patients with *RUNX1* expression data and clinical information. The results showed that *RUNX1* was highly expressed in female patients and white race. Higher *RUNX1* expression was associated with advanced TNM stage and poor histological grade stage. The results were consistent with that *RUNX1* might be an unfavorable factor for KIRC patients. Furthermore, we performed Cox regression analysis, and results showed stage and age were significantly associated with OS in KIRC patients (Figure 3A). Then Multivariate Cox regression analysis showed that stage was an independent factor influencing KIRC prognosis (Figure 3B).

### **Analysis of promoter methylation status and protein expression of *RUNX1* gene in KIRC**

To explore the hinge of *RUNX1* expression, we investigated the promoter methylation level of *RUNX1* in KIRC by UALCAN. Twelve probes in *RUNX1* promoter were used for detecting DNA methylation level of *RUNX1* (Figure 4A). Notably, primary tumor tissues had obviously lower promoter methylation levels than normal tissues ( $p < 0.001$ , Figure 4B). Meanwhile, it was a significant inverse correlation between DNA methylation level of *RUNX1* gene and its mRNA expression in KIRC samples (*Spearman* = -0.69,  $p = 1.33e-46$ ; *Pearson* = -0.60,  $p = 1.19e-32$ , Figure 4C) based on cBioPortal analysis. The results indicated that upregulated expression of *RUNX1* was associated with DNA hypomethylation, and it could be considered as a risk factor for KIRC. Surprisingly, the prognosis analysis showed that patients with promoter hypomethylation of *RUNX1* had a worse OS ( $p < 0.001$ , Figure 4D). Furthermore, we compared the protein expression of *RUNX1* in normal and KIRC tissues, verifying that the expression level of *RUNX1* protein was indeed significantly elevated in KIRC ( $p < 0.001$ , Figure 4E).

### **Enrichment analysis of *RUNX1* gene functional networks in KIRC**

As shown in the volcano plot using LinkedOmics analysis (Figure 5A), red spots represent genes

positively correlated with *RUNXI* in KIRC, while green spots represent genes with a negative correlation. Furthermore, the top 50 significant gene correlated positively or negatively with *RUNXI* were shown in the heat maps (Figure 5B, 5C), which suggested a widespread impact of *RUNXI* in the transcription. In addition, GSEA showed varying expression of *RUNXI* gene mainly in the receptor complex, cell-substrate junction and apical part of cell, which primarily participated in adaptive immune response, leukocyte migration and protein targeting. They played a key role in receptor-ligand activity, protein tyrosine kinase activity, transferase activity, and transferring acyl groups (Figure 6A-C). KEGG pathway analysis showed that the differentially expressed genes were mainly enriched in proteoglycans in cancer, microRNAs in cancer, focal adhesion and peroxisome (Figure 6D-6F). To further explore the targets of *RUNXI* gene in KIRC, we analyzed the transcription factors and kinase targets of positively correlated gene sets generated by GSEA (Table 3). The top 3 most significant kinase target networks related to LYN proto-oncogene, p21 activated kinase 1(*PAKI*) and HCK proto-oncogene3. The transcription factor target network was mainly related with *ETS1*, *NFKAPPAB*, *MZF1*, *IRF*, *SRF*.

## Discussions

The *RUNX* family has been noticed to play an important role in leukemia and solid tumors. Known as one of the most frequently mutated genes in human leukemia, *RUNXI* was originally identified to have a role in hematopoiesis<sup>[29]</sup>. Increasingly, it has been implicated in cancers of ovary<sup>[30]</sup>, prostate<sup>[31]</sup> and stomach<sup>[32]</sup>, which was associated<sup>[31]</sup> with either gain or loss of *RUNXI* function. Recently, Yang et al. revealed that higher *RUNXI* expression may be associated with poorer survival in RCC<sup>[33]</sup>; this was later confirmed by Rooney et al. who utilized a genetically engineered mouse (GEM) model<sup>[18]</sup>. According to a recent research from Kamikudo et al., as the *RUNX* family has a mechanism to compensate for loss among the family members, it is difficult to individually inhibit *RUNX* family proteins, *RUNX* family cluster regulation<sup>[34]</sup> might be a cancer treatment strategy. However, As Lie-a-ling mentioned, although it has become evident that expression level of *RUNXI* can be used as a marker of tumor progression<sup>[35]</sup>, it is not yet fully uncovered how the alteration contributes to tumorigenesis, since both the amount and activation status of proteins can have effects. Therefore, we performed comprehensive analyses of the expression levels of *RUNX* genes in kidney cancer.

Our study showed that compared to normal kidney tissues, the expression levels of *RUNXI* and



*RUNX3* were increased in KIRC cases. Prognostic studies further suggested that higher expression of *RUNX1* gene was significantly associated with poorer OS in KIRC. Interestingly, the low methylation level of the *RUNX1* gene promoter was found to be significantly related to its high mRNA and protein expression and, consequently, to the poor OS of KIRC. The methylation-mediated expression regulation of *RUNX3* has been observed to play a role in leukemia and solid tumors. Marcos et al. found that *RUNX3* hypermethylation was a worse prognosis in leukemia<sup>[36]</sup> and Avci et al. emphasized the methylated allele of *RUNX3* as a significant inducer in human brain tumors<sup>[37]</sup>. More importantly, Cen et al. found a connection between higher level of *RUNX3* methylation and poorer OS in KIRC<sup>[38]</sup>. Our results showed significantly elevated expression of *RUNX3* in KIRC tissues. However, no significant relationship between the methylation level of *RUNX3* and OS was noticed, which deserved further research.

Recent studies have found overexpression of *RUNX1* in mouse models of kidney fibrosis, which is related to KIRC, indicating *RUNX1* has a regulation of TGF $\beta$ -driven epithelial-to-mesenchymal transition (EMT)<sup>[39]</sup>. Recently, Young et al. indicated that *RUNX1*, which had a relationship with multiple signaling pathways including *JAK/STAT*, *MAPK*, *p53* and *VEGF*, could be recognized as a novel therapeutic target and prognostic factor<sup>[40]</sup>. Kamikudo et al. found that moderate inhibition of *RUNX1* most significantly increased the total level of *RUNX* family through “genetic compensation of *RUNX* family transcription factors”, emphasized the role of *RUNX1* in tumorigenesis<sup>[41]</sup>. Furthermore, Zhao et al. manifested that PRMT1-dependent methylation of *RUNX1* likely contributed to its inhibitory activity<sup>[15]</sup>. Considering our findings, patients with higher transcription levels of *RUNX1* had worse prognosis, which corresponded to lower levels of promoter methylation. The results suggested that the promoter methylation of *RUNX1* occurred in many KIRC cases and deserved to be seen as a potential diagnostic and prognostic marker.

Previous studies suggested that *RUNX1* was critical in a variety of genes transcription and played a role in cellular regulation. It has been recognized that genomic instability and mutagenesis are essential features of cancer cells, and kinases and their associated signaling pathways help stabilize and repair genomic DNA<sup>[42, 43]</sup>. Ballissimo et al. noticed that cells with inefficient *RUNX1* showed defects in DNA repair, including base excision, homologous recombination and DNA interstrand crosslink repair<sup>[44]</sup>. Sanoji et al. also proved that *RUNX1* was involved in cell cycle arrest and apoptosis, as a

potential factor in cancer formation<sup>[45]</sup>. In order to clarify the role *RUNXI* in KIRC, we tried to locate its target kinases and transcription factors by LinkedOmics, and found an extensive connection with them, indicating that *RUNXI* was rather involved in cellular regulation. Furthermore, GSEA was performed to identify significantly enriched or depleted groups of genes. The results showed that *RUNXI* was mainly responsible for adaptive immune response, leukocyte migration and protein targeting. In addition, *RUNXI* mainly participated in peroxisome, microRNA and proteoglycans in cancers. We assume that these participations are likely to make *RUNXI* an initiator of KIRC.

In conclusion, we performed an integrated analysis about the expression and prognostic value of RUNX genes in kidney cancer. Our results showed that *RUNXI* and *RUNX3* were upregulated in the tissues of KIRC compared to the normal ones. Furthermore, the results revealed that *RUNXI* was a potential therapeutic target for KIRC, and that lower promoter methylation level of *RUNXI* indicated poorer survival. Generally, we assumed *RUNXI* may be a potential diagnostic and prognostic marker for KIRC, and its abnormal methylation may participate in tumorigenesis, which lay a foundation for further study.

#### Availability of data and materials

Patients data were acquired from Oncomine (<https://www.oncomine.org/>), GEPIA2 (<http://gepia2.cancer-pku.cn>), cBioportal (<https://www.cbioportal.org/>), UALCAN (<http://ualcan.path.uab.edu>), KM Plotter (<http://kmplot.com/analysis/>), and LinkedOmics (<http://linkedomics.org>) database tool. We have referred expression profiling, DNA methylation level and protein expression profile of RUNX genes.

#### Conflicts of Interest

The authors declare no conflict of interest.

#### Funding Source

The Talent Fund Project of the Second Affiliated Hospital of Xi'an Jiaotong University (No. RC-XM-201802).

#### Ethical Approval

No ethical approval was obtained because this study did not involve a clinical evaluation, did not involve laboratory animals and invasive procedures.

#### Author Contributions

KG and ZMD developed the idea and designed the research. KC, MLX and FZ analyzed the data. KG, YBG and WL drafted the manuscript. TC and ZMD revised the writing. All authors read and approved the submitted version.

#### References:

1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. **Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.** *CA: a cancer journal for clinicians* 2018; 68(6).
2. Bamias A, Escudier B, Sternberg CN, et al. **Current Clinical Practice Guidelines for the Treatment of Renal Cell Carcinoma: A Systematic Review and Critical Evaluation.** *The oncologist* 2017; 22(6).
3. Choueiri TK, Larkin J, Oya M, et al. **Preliminary results for avelumab plus axitinib as first-line therapy in patients with advanced clear-cell renal-cell carcinoma (JAVELIN Renal 100): an open-label, dose-finding and dose-expansion, phase 1b trial.** *The Lancet Oncology* 2018; 19(4).
4. Seo W, Taniuchi I. **The Roles of RUNX Family Proteins in Development of Immune Cells.** *Molecules and cells* 2020; 43(2).
5. Richiardi L, Fiano V, Vizzini L, De Marco L, Delsedime L, Akre O, et al. **Promoter methylation in APC, RUNX3, and GSTP1 and mortality in prostate cancer patients.** *Journal of clinical oncology : official journal of the American Society of Clinical Oncology* 2009; 27(19):3161-3168.
6. Lu Y, Zabihula B, Yibulayin W, Liu X. **Methylation and expression of RECK, P53 and RUNX genes in patients with esophageal cancer.** *Oncology letters* 2017; 14(5):5293-5298.
7. Zheng J, Mei Y, Xiang P, Zhai G, Zhao N, Xu C, et al. **DNA methylation affects metastasis of renal cancer and is associated with TGF- $\beta$ /RUNX3 inhibition.** *Cancer Cell International* 2018; 18(1):56.
8. Blyth K, Cameron ER, Neil JC. **The runx genes: gain or loss of function in cancer.** *Nature Reviews Cancer* 2005; 5(Suppl. 32).
9. Ito Y, Bae SC, Chuang LS. **The RUNX family: developmental regulators in cancer.** *Nature reviews Cancer* 2015; 15(2).
10. Neil JC, Gilroy K, Borland G, Hay J, Terry A, Kilbey A. **The RUNX Genes as Conditional Oncogenes: Insights from Retroviral Targeting and Mouse Models.** *Advances in experimental medicine and biology* 2017; 962.
11. Mizutani S, Yoshida T, Zhao X, Nimer SD, Taniwaki M, Okuda T. **Loss of RUNX1/AML1 arginine-methylation impairs peripheral T cell homeostasis.** *British journal of haematology* 2015; 170(6):859-873.
12. Mercado-Matos J, Matthew-Onabanjo AN, Shaw LM. RUNX1 and breast cancer. *Oncotarget.* 2017;8(23):36934-36935.
13. Chingge NO, Little GH, Baniwal SK, et al. **RUNX1 prevents oestrogen-mediated AXIN1 suppression and  $\beta$ -catenin activation in ER-positive breast cancer.** *Nature communications* 2016; 7.
14. Jin YH, Jeon EJ, Li QL, et al. **Transforming Growth Factor- $\beta$  Stimulates p300-dependent RUNX3 Acetylation, Which Inhibits Ubiquitination-mediated Degradation.** *Journal of Biological Chemistry*; 279(28):29409-29417.
15. Zhao X, Jankovic V, Gural A, et al. **Methylation of RUNX1 by PRMT1 abrogates SIN3A binding and potentiates its transcriptional activity.** *Cold Spring Harbor Laboratory Press* 2008; 22(5).
16. Guo H, Friedman AD. **Phosphorylation of RUNX1 by cyclin-dependent kinase reduces direct interaction with HDAC1 and HDAC3.** *The Journal of biological chemistry* 2011; 286(1).

17. Kim JH, Jang JW, Lee YS, et al. **RUNX family members are covalently modified and regulated by PIAS1-mediated sumoylation.** *Oncogenesis* 2014; 3.
18. Rooney N, Mason SM, McDonald L, Däbritz JHM, Campbell KJ, Hedley A, et al. **RUNX1 Is a Driver of Renal Cell Carcinoma Correlating with Clinical Outcome.** *Cancer Res* 2020; 80(11):2325-2339.
19. Chen F, Liu X, Cheng Q, Zhu S, Bai J, Zheng J. **RUNX3 regulates renal cell carcinoma metastasis via targeting miR-6780a-5p/E-cadherin/EMT signaling axis.** *Oncotarget* 2017; 8(60).
20. R RD, Shanker K-S, Vasudeva M, Radhika V, Jianjun Y, B BB, et al. **Oncomine 3.0: genes, pathways, and networks in a collection of 18,000 cancer gene expression profiles.** *Neoplasia (New York, NY)* 2007; 9(2).
21. Rhodes DR, Kalyana-Sundaram S, Mahavisno V, et al. **GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses.** *Nucleic acids research* 2017; 45(W1).
22. Nagy Á, Lániczky A, Menyhárt O, Györfly B. **Author Correction: Validation of miRNA prognostic power in hepatocellular carcinoma using expression data of independent datasets.** *Scientific reports* 2018; 8(1).
23. Chandrashekar DS, Bashel B, Balasubramanya SAH, et al. **UALCAN: A Portal for Facilitating Tumor Subgroup Gene Expression and Survival Analyses.** *Neoplasia (New York, NY)* 2017; 19(8).
24. Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, et al. **The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data.** *Cancer Discov* 2012; 2(5):401-404.
25. Men C, Chai H, Song X, Li Y, Du H, Ren Q. **Identification of DNA methylation associated gene signatures in endometrial cancer via integrated analysis of DNA methylation and gene expression systematically.** *J Gynecol Oncol* 2017; 28(6):e83.
26. Shinawi T, Hill VK, Krex D, Schackert G, Gentle D, Morris MR, et al. **DNA methylation profiles of long- and short-term glioblastoma survivors.** *Epigenetics* 2013; 8(2):149-156.
27. Vasaikar SV, Straub P, Wang J, Zhang B. **LinkedOmics: analyzing multi-omics data within and across 32 cancer types.** *Nucleic acids research* 2018; 46(D1).
28. Liberzon A, Subramanian A, Pinchback R, Thorvaldsdottir H, Tamayo P, Mesirov JP. **Molecular signatures database (MSigDB) 3.0.** *Bioinformatics* 2011; 27(12):1739-1740.
29. Okuda T, van Deursen J, Hiebert SW, Grosveld G, Downing JR. **AML1, the target of multiple chromosomal translocations in human leukemia, is essential for normal fetal liver hematopoiesis.** *Cell* 1996; 84(2).
30. Alcalay M, Meani N, Gelmetti V, et al. **Acute myeloid leukemia fusion proteins deregulate genes involved in stem cell maintenance and DNA repair.** *The Journal of clinical investigation* 2003; 112(11).
31. Takayama K, Suzuki T, Tsutsumi S, et al. **RUNX1, an androgen- and EZH2-regulated gene, has differential roles in AR-dependent and -independent prostate cancer.** *Oncotarget* 2015; 6(4).
32. Mitsuda Y, Morita K, Kashiwazaki G, et al. **RUNX1 positively regulates the ErbB2/HER2 signaling pathway through modulating SOS1 expression in gastric cancer cells.** *Scientific reports* 2018; 8(1).
33. Fu Y, Sun S, Man X, Kong C. **Increased expression of RUNX1 in clear cell renal cell carcinoma predicts poor prognosis.** *PeerJ* 2019; 7:e7854.
34. Kamikubo Y. **CROX (Cluster Regulation of RUNX) as a Potential Novel Therapeutic Approach.** *Mol Cells* 2020; 43(2):198-202.
35. Lie-A-Ling M, Mevel R, Patel R, et al. **RUNX1 Dosage in Development and Cancer.** *Mol Cells* 2020; 43(2):126-138.
36. Estécio MRH, Maddipoti S, Bueso-Ramos C, Dinardo CD, Yang H, Wei Y, et al. **RUNX3 promoter hypermethylation is frequent in leukaemia cell lines and associated with acute myeloid leukaemia inv(16) subtype.** *British Journal of Haematology* 2015; 169(3):344-351.
37. Avci CB, Dodurga Y, Susluer SY, et al. **Promoter hypermethylation-mediated down-regulation of RUNX3 gene in human brain tumors.** *Irish Journal of Medical Science* 2013; 183(2):259.

38. Cen D, Xu L, Zhang S, et al. **Renal cell carcinoma: predicting RUNX3 methylation level and its consequences on survival with CT features.** *European Radiology* 2019.
39. Wang H. **Runt-Related Transcription Factor 1 (RUNX1) Promotes TGF- $\beta$ -Induced Renal Tubular Epithelial-to-Mesenchymal Transition (EMT) and Renal Fibrosis through the PI3K Subunit p110 $\delta$ .** *Ebiomedicine* 2018.
40. Sun CC, Li SJ, Chen ZL, Li G, Zhang Q, Li DJ **Expression and Prognosis Analyses of Runt-Related Transcription Factor Family in Human Leukemia.** *Molecular therapy oncolytics* 2019; 12.
41. Kamikubo Y. **Genetic compensation of RUNX family transcription factors in leukemia.** *Cancer Sci* 2018; 109(8):2358-2363.
42. Yogosawa S, Yoshida K. **Tumor suppressive role for kinases phosphorylating p53 in DNA damage-induced apoptosis.** *Cancer Science* 2018; 109(11).
43. Karimian A, Ahmadi Y, Yousefi B. **Multiple functions of p21 in cell cycle, apoptosis and transcriptional regulation after DNA damage.** *DNA repair* 2016; 42.
44. Bellissimo DC, Speck NA. **RUNX1 Mutations in Inherited and Sporadic Leukemia.** *Frontiers in cell and developmental biology* 2017; 5.
45. Samarakkody AS, Shin NY, Cantor AB. **Role of RUNX Family Transcription Factors in DNA Damage Response.** *Molecules and cells* 2020; 43(2).

**Table 1.** Differential expression level analysis of RUNX genes in different types of kidney cancer

Gene	Types of Renal Cancer	Author	Fold change	P	T
<i>RUNX1</i>	KIRC	Yusenko MV	6.58	2.65E-14	13.63
	KIRP	Yusenko MV	2.93	4.30E-06	5.82
	KIRC	Gumz ML	6.51	4.94E-06	6.71
	NHRCC	Beroukhim R	3.08	8.18E-07	6.11
	HRCC	Beroukhim R	3.52	9.04E-08	7.39
<i>RUNX2</i>	KIRC	Yusenko MV	3.35	8.30E-06	5.57
	Renal Oncocytoma	Yusenko MV	-3.47	7.31E-05	-7.45
	KICH	Jones J	-4.92	1.32E-07	-20.66
	Renal Oncocytoma	Jones J	-4.12	3.05E-12	-19.16
<i>RUNX3</i>	HRCC	Beroukhim R	3.7	6.24E-13	11.28
	NHRCC	Beroukhim R	2.45	1.33E-07	6.33
	KIRC	Gumz ML	8.32	2.30E-05	5.34
	KIRC	Jones J	2.7	8.70E-10	9.08
	KIRC	Yusenko MV	4.45	3.27E-04	6.08

The significance of bold means p-value < 0.05. KIRC: kidney renal clear cell carcinoma, KIRP: kidney renal papillary cell carcinoma, NHRCC: non-hereditary renal clear cell carcinoma, HRCC: hereditary renal clear cell carcinoma, KICH: kidney chromophobe renal cell carcinoma.

**Table 2.** The clinical characteristics about RUNX1 expression in KIRC patients

Characteristic		RUNX1 <sup>FPKM</sup>	%
Numbers of patients, n	531		
Median age, years	61(26-90)		
Gender, n			
Male	344	4.00 (0.1-36.5)	64.78
Female	187	3.10 (0.5-15.7)	35.22
Age, n			
< 65 years	332	3.60 (0.3-36.5)	62.52
≥ 65 years	199	3.55 (0.1-19.8)	37.48
Race, n			
White	462	3.70 (0.2-36.5)	87.01
Non-white	64	2.95 (0.5-11.1)	12.05
Not known	5	1.80	0.94
TNM Stage, n			
Stage I + II	324	3.20 (0.1-21.9)	61.02
Stage III+IV	207	4.40 (0.5-36.5)	38.98
Grade, n			
Grade I + II	243	3.26 (0.21-21.9)	45.76
Grade III+IV	282	4.95 (0.7-36.5)	53.11

FPKM: Fragments per Kilobase Million

**Table 3.** Targets transcription factor and kinase of *RUNX1* gene in KIRC from Linkedomics

Enriched Category	Gene Set	Size	Leading Edge	P-Value	FDR*
			Number		
TF-Target	ETS1	237	93	< 0.001	0.000979
	NFKAPPAB	242	103	< 0.001	0.001305
	MZF1	217	75	< 0.001	0.001958
	IRF	229	85	< 0.001	0.002238
	SRF	201	65	< 0.001	0.002284
Kinase-Target	Kinase_LYN	50	24	< 0.001	0.006727
	Kinase_PAK1	50	15	< 0.001	0.00897


TF: transcription factor, FDR: False discovery rate, \*: FDR < 0.05

Analysis Type by Cancer	Cancer vs. Normal		Cancer vs. Normal		Cancer vs. Normal	
	RUNX1		RUNX2		RUNX3	
Bladder Cancer	1					1
Brain and CNS Cancer	4					
Breast Cancer	5		6		1	
Cervical Cancer	1				2	
Colorectal Cancer	7		1	1		1
Esophageal Cancer	2		2		2	
Gastric Cancer						
Head and Neck Cancer	7		2		3	
Kidney Cancer	5		1	3	5	
Leukemia	9	1		7	1	5
Liver Cancer			1		2	
Lung Cancer	1	1	3			
Lymphoma	1	3		1	1	3
Melanoma		2	1		1	
Myeloma	1					
Other Cancer	7		5			
Ovarian Cancer					1	
Pancreatic Cancer	3		2		1	
Prostate Cancer		1		2		
Sarcoma	5					
Significant Unique Analyses	58	7	24	14	19	10
Total Unique Analyses	460		450		447	




**Figure 1.** OncoPrint analysis of the mRNA expression levels of *RUNX* genes in different cancers. The differences in expression levels of genes between cancer and normal tissues are concluded. The thresholds (p-value < 0.01, fold change > 2; gene rank < 10%; data type: mRNA) are indicated in the colored cells. Red cells represent overexpression of the target gene in tumor tissues compared to normal tissues, while blue cells indicate downregulation of the gene. Gene rank is depicted by the color depth in the cells.







**Figure 2.** (A-C) GEPIA analysis results of the mRNA expression level of *RUNX* genes in different types of kidney cancer. Box plots of individual *RUNX* expression in KIRC tissues and paired normal tissues, \*: p-value < 0.05. (D-E) Correlation analysis between *RUNX1* and *RUNX3* expressions and overall survival in KIRC patients by Kaplan-Meier plotter. KICH: kidney chromophobe renal cell carcinoma KIRC: kidney renal clear cell carcinoma, KIRP: kidney renal papillary cell carcinoma.





**Figure 3.** Stage and age were significantly associated with OS in KIRC patients. (A) Univariate Cox regression analysis of correlations between OS and clinical variables. (B) Multivariate Cox regression analysis of correlations between OS and clinical variables.

**A Probes for detecting DNA methylation of RUNX1 promoter**


Illumina Id	RefGene_group
cg13521940	TSS1500
cg02635869	TSS1500
cg11564339	TSS1500
cg16066237	TSS200
cg07961283	TSS200
cg04357830	TSS1500
cg23508333	TSS200
cg15242225	TSS1500
cg03017480	TSS200
cg01337293	TSS1500
cg08443845	TSS1500
cg19836199	TSS1500




**D RUNX1 vs overall survival (0 <= Median) (1 > Median) Median=0.1027 Sample Size:(N=307)**



**Figure 4.** DNA methylation aberration of *RUNX1* in KIRC. A. Probes for detecting DNA methylation of *RUNX1* promoter. B. UALCAN analysis about the promoter methylation levels of *RUNX1* in KIRC and normal samples. C. The correlation analysis between the promoter methylation level of *RUNX1* and its expression level based on cBioPortal database. D. Correlation analysis between the promoter methylation level of *RUNX1* and overall survival in KIRC patients by LinkedOmics. E. CPTAC analysis about the comparison of *RUNX1* protein expression between normal and KIRC tissues. KIRC: kidney renal clear cell carcinoma.



**Figure 5.** Genes differentially expressed in correlation with *RUNX1* in KIRC by LinkedOmics. (A) Volcano plots in analyzing differential expression genes correlated with *RUNX1* in KIRC. (B&C) Heat maps showing genes positively and negatively correlated with *RUNX1* in KIRC (TOP 50). Red indicates positively correlated genes and blue indicates negatively correlated genes.



**Figure 6.** Significantly enriched GO annotations and KEGG pathways of *RUNX1* in KIRC were analyzed using GSEA. (A) Cellular components. (B) Biological processes. (C) Molecular functions. (D) KEGG pathway analysis. KEGG pathway annotations of the cell cycle pathway, (E) Peroxisome biogenesis, (F) MicroRNAs in cancer. Red marked nodes are associated with the LeadingEdgeGene.

# Figures

Analysis Type by Cancer	Cancer vs. Normal		Cancer vs. Normal		Cancer vs. Normal	
	RUNX1		RUNX2		RUNX3	
Bladder Cancer	1					1
Brain and CNS Cancer	4					
Breast Cancer	5		6		1	
Cervical Cancer	1				2	
Colorectal Cancer	7		1	1		1
Esophageal Cancer	2		2		2	
Gastric Cancer						
Head and Neck Cancer	7		2		3	
Kidney Cancer	5		1	3	5	
Leukemia	9	1		7	1	5
Liver Cancer			1		2	
Lung Cancer	1	1	3			
Lymphoma	1	3		1	1	3
Melanoma		2	1		1	
Myeloma	1					
Other Cancer	7		5			
Ovarian Cancer					1	
Pancreatic Cancer	3		2		1	
Prostate Cancer		1		2		
Sarcoma	5					
Significant Unique Analyses	58	7	24	14	19	10
Total Unique Analyses	460		450		447	




Figure 1

Oncomine analysis of the mRNA expression levels of RUNX genes in different cancers. The differences in expression levels of genes between cancer and normal tissues are concluded. The thresholds (p-value < 0.01, fold change > 2; gene rank < 10%; data type: mRNA) are indicated in the colored cells. Red cells




represent overexpression of the target gene in tumor tissues compared to normal tissues, while blue cells indicate downregulation of the gene. Gene rank is depicted by the color depth in the cells.



**Figure 2**

(A-C) GEPIA analysis results of the mRNA expression level of RUNX genes in different types of kidney cancer. Box plots of individual RUNX expression in KIRC tissues and paired normal tissues, \*: p-value < 0.05. (D-E) Correlation analysis between RUNX1 and RUNX3 expressions and overall survival in KIRC

patients by Kaplan-Meier plotter. KICH: kidney chromophobe renal cell carcinoma KIRC: kidney renal clear cell carcinoma, KIRP: kidney renal papillary cell carcinoma.





**Figure 3**



Stage and age were significantly associated with OS in KIRC patients. (A) Univariate Cox regression analysis of correlations between OS and clinical variables. (B) Multivariate Cox regression analysis of correlations between OS and clinical variables.

**A Probes for detecting DNA methylation of RUNX1 promoter**

Illumina Id	RefGene_group
cg13521940	TSS1500
cg02635869	TSS1500
cg11564339	TSS1500
cg16066237	TSS200
cg07961283	TSS200
cg04357830	TSS1500
cg23508333	TSS200
cg15242225	TSS1500
cg03017480	TSS200
cg011337293	TSS1500
cg08443845	TSS1500
cg19836199	TSS1500




**D RUNX1 vs overall\_survival (0 <= Median) (1 > Median) Median=0.1027 Sample Size:(N=307)**



**Figure 4**



DNA methylation aberration of RUNX1 in KIRC. A. Probes for detecting DNA methylation of RUNX1 promoter. B. UALCAN analysis about the promoter methylation levels of RUNX1 in KIRC and normal samples. C. The correlation analysis between the promoter methylation level of RUNX1 and its expression level based on cBioPortal database. D. Correlation analysis between the promoter methylation level of RUNX1 and overall survival in KIRC patients by LinkedOmics. E. CPTAC analysis about the comparison of RUNX1 protein expression between normal and KIRC tissues. KIRC: kidney renal clear cell carcinoma.



**Figure 5**

Genes differentially expressed in correlation with RUNX1 in KIRC by LinkedOmics. (A) Volcano plots in analyzing differential expression genes correlated with RUNX1 in KIRC. (B&C) Heat maps showing genes positively and negatively correlated with RUNX1 in KIRC (TOP 50). Red indicates positively correlated genes and blue indicates negatively correlated genes.

